Trial | NCT01161654  Report issue

Title

Bioequivalency Study of Naratriptan Hydrochloride 2.5 mg Under Fed Conditions
A Single Dose, Two-Period, Two-Treatment, Two-Way Crossover Bioequivalence Study of Naratriptan Hydrochloride 2.5 mg Tablets Under Fed Conditions

  • Phase

    N/A

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Intervention/Treatment

    naratriptan ...

  • Study Participants

    33
The objective of this study was to prove the bioequivalence of Naratriptan Hydrochloride Tablet under fed conditions.
Study Started
Aug 31
2007
Primary Completion
Sep 30
2007
Study Completion
Sep 30
2007
Last Update
Jan 23
2018

Drug naratriptan hydrochoride

2.5 mg tablet

  • Other names: AMERGE

Criteria 

Inclusion Criteria:

No clinically significant abnormal findings on the physical examination, medical history, or clinical laboratory results during screening

Exclusion Criteria:

Positive test for HIV, Hepatitis B, or Hepatitis C.
Treatment with known enzyme altering drugs.
History of allergic or adverse response to naratriptan hydrochloride or any comparable or similar product.
No Results Posted